NCT02842749 - Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 14, 2016

Primary Completion Date

February 22, 2024

Study Completion Date

February 22, 2024

Conditions

Pancreatic Neuroendocrine Tumors

Interventions

DRUG

everolimus

Participants were instructed to take everolimus at a starting dose of 10 mg orally once daily. However, dose adjustments were permitted in order to allow the participant to continue the study treatment.

Trial Locations (5)

100039

Novartis Investigative Site, Beijing

100730

Novartis Investigative Site, Beijing

200032

Novartis Investigative Site, Shanghai

510060

Novartis Investigative Site, Guangzhou